Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Al18F-octreotide PET/CT in SSTR Positive Tumors
NCT05749289Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2022
- Primary completion
- Dec 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of 18F-AlF-NOTA-octreotide in Neoplasm, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Dec 2022; status: recruiting.
02
Drugs
18F-AlF-NOTA-octreotide
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT05749289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05749289.